Clinical Trial Update: AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites [Phase 2]

View source ↗

Summary

Phase 2 study of AZD9150 (danvatirsen), a STAT3 antisense oligonucleotide, in patients with malignant ascites associated with ovarian or gastrointestinal cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Cancer
• Ovarian Cancer

Drugs mentioned

• AZD9150

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Ovarian Cancer, Ovarian Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2017-05-15